• ErdemHüseyin AytaçHA0000-0001-7375-977XDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, İzmir, Turkey, Pervin Ekren Korkma, Derya Çağlayan, Meltem Işıkgöz Taşbakan, Tansu Yamazhan, Mehmet Sezai Taşbakan, Abdullah Sayıner, and Deniz Gökengin.
• Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Ege University, İzmir, Turkey
• Turk J Med Sci. 2021 Jun 28; 51 (3): 912920912-920.

Background/AimThe aim of this descriptive article is to share the experience in Ege University, Turkey with favipiravir in the treatment of severe SARS-CoV-2 pneumonia.Materials And MethodsThis retrospective descriptive study included patients diagnosed with COVID-19 who presented with or developed severe pneumonia.ResultsForty patients who completed a full course (at least 5 days) of favipiravir were included in the study. At baseline, 30 (75%) patients required treatment for respiratory distress. Thirty-three patients (82.5%) were discharged from the hospital with full recovery, 6 patients (15%) died and 1 case (2.5%) was still at the intensive care unit (ICU) when this paper was written.ConclusionThis study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.This work is licensed under a Creative Commons Attribution 4.0 International License.

29 keywords...

hide…